

## Bulletin from the annual general meeting in NeoDynamics AB (publ)

**The annual general meeting in NeoDynamics AB (publ) was held on 23 May 2023 at the company's premises on Lejonvägen 14, Lidingö, whereby the shareholders primarily resolved on the following matters.**

### **Annual report and result**

The annual report and the auditor's report for the financial year 2022 were presented and the income statement and balance sheet included in the annual report were adopted.

It was resolved to not pay any dividends and that the company's result shall be retained in the business.

### **Discharge from liability**

The annual general meeting resolved to grant each of the members of the board of directors and the CEO discharge from liability in respect of the company for the financial year 2022.

### **Remuneration**

It was resolved that remuneration shall be paid with SEK 200,000 to the chairman of the board, and with SEK 125,000 to each other member of the board.

It was further resolved that remuneration shall be paid to the auditor in accordance with approved invoice.

### **Board of directors**

The annual general meeting resolved that the board shall consist of four (4) ordinary members without deputy members.

It was resolved to reelect Carina Bolin, Claes Pettersson, Ingrid Salén and Matthew E. Colpoys, Jr. as board members for the period until the end of the next annual general meeting. Ingrid Salén was reelected as chairman of the board.

### **Auditor**

The annual general meeting resolved that one auditor, without deputy auditors, shall be appointed.

It was resolved to elect Ernst & Young AB (EY) as auditor, with Jakob Wojcik as principal auditor, for the period until the end of the next annual general meeting.

### **NeoDynamics AB 2023 Stock Option Plan, directed issue of warrants and approval of transfer**

The annual general meeting resolved in accordance with the board of directors' proposal to establish an employee stock option program intended for senior executives, employees and consultants with US tax residency. The employee stock option program shall comprise of not more than 1,700,000 shares.

To enable the company's delivery of shares under the employee stock option program, the annual general meeting resolved on a directed issue of not more than 1,700,000 warrants. The right to subscribe for the warrants vests with NeoDynamics.

The annual general meeting further resolved to approve the transfer of warrants or shares in the Company to participants in the employee stock option program.

Detailed contents of the resolutions are stated in the notice convening the general meeting and the board of directors' full proposal.

## **Authorizations**

### *Rights issue*

The annual general meeting resolved to authorize the board of directors, for the time until the next annual general meeting, whether on one or several occasions, to resolve on issues of shares, warrants and/or convertible instruments. The board of directors shall be able to resolve on issues of shares, warrants and/or convertible instruments. Any such issue shall be with preferential rights for the shareholders.

### *Directed issue(s)*

Finally, the annual general meeting resolved to authorize the board of directors to, on one or several occasions during the period up to the next annual general meeting, increase the Company's share capital through issues of new shares, warrants and/or convertible instruments, with or without provisions on payment by non-cash consideration and/or by way of set-off or other provisions. The board of directors shall not be able to make decisions that mean that the amount by which the share capital is increased corresponds to more than fifty (50) percent of the total share capital in the Company when the authorization is utilized for the first time.

## **For further information, please contact:**

Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail [anna.eriksrud@neodynamics.com](mailto:anna.eriksrud@neodynamics.com)

Aaron Wong, CFO NeoDynamics AB, phone +46790 101 714 or e-mail [aaron.wong@neodynamics.com](mailto:aaron.wong@neodynamics.com)

## **About NeoDynamics**

NeoDynamics AB is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company's first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and launches in USA during 2023. NeoDynamic's shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company's Certified Adviser is Redeye AB.

## **About NeoNavia**

NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumor whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.

## **About Karolinska Institute**

The Karolinska Institute is consistently ranked amongst the world's best medical schools, ranking 6th worldwide for medicine in 2021. The Nobel Assembly at the Karolinska Institute awards the Nobel Prize in Physiology or Medicine.

## Attachments

[Bulletin from the annual general meeting in NeoDynamics AB \(publ\)](#)